Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Glycated hemoglobin

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44339   clinical trials with a EudraCT protocol, of which   7369   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    66 result(s) found for: Glycated hemoglobin. Displaying page 1 of 4.
    1  2  3  4  Next»
    EudraCT Number: 2017-000092-84 Sponsor Protocol Number: EFC15082 Start Date*: 2019-06-03
    Sponsor Name:Sanofi-aventis recherche & développement
    Full Title: A 26-week, Randomized, Open-label, Parallel-group Comparison of SAR341402 Mix 70/30 to NovoMix®30 in Adult Patients with Diabetes Mellitus Using Pre-mix Insulin Analogs
    Medical condition: Type 1 Diabetes Mellitus Type 2 Diabetes Mellitus
    Disease: Version SOC Term Classification Code Term Level
    20.0 10027433 - Metabolism and nutrition disorders 10067584 Type 1 diabetes mellitus PT
    20.0 10027433 - Metabolism and nutrition disorders 10067585 Type 2 diabetes mellitus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Completed)
    Trial results: View results
    EudraCT Number: 2017-002956-10 Sponsor Protocol Number: EFC14829 Start Date*: 2019-02-27
    Sponsor Name:sanofi-aventis recherche & développement
    Full Title: A 56-week, Multicenter, Open-label, Active-controlled, Randomized Study to Evaluate the Efficacy and Safety of Efpeglenatide Once Weekly Compared to Dulaglutide Once Weekly in Patients with Type 2 ...
    Medical condition: Type 2 Diabetes Mellitus
    Disease: Version SOC Term Classification Code Term Level
    21.1 10027433 - Metabolism and nutrition disorders 10067585 Type 2 diabetes mellitus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2017-003370-13 Sponsor Protocol Number: LPS15017 Start Date*: 2018-10-10
    Sponsor Name:Sanofi-Aventis Groupe
    Full Title: A multi-center open-label parallel group randomized controlled trial to compare iGlarLixi versus premixed insulin in patients with type 2 diabetes who have failed to achieve glycemic control with b...
    Medical condition: Patients with Type 2 Diabetes who have failed to achieve glycemic control with basal insulin and oral antidiabetic agents(OADs)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10027433 - Metabolism and nutrition disorders 10067585 Type 2 diabetes mellitus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) AT (Completed) ES (Completed) SE (Completed) BG (Completed) GR (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2012-005370-62 Sponsor Protocol Number: ANAKIN-RA-DIABETES Start Date*: 2013-02-18
    Sponsor Name:OSPEDALE CIVILE SAN SALVATORE, ASL 04, L'AQUILA
    Full Title: “No-profit” clinical study for the improvement of clinical practice, to evaluate the efficacy of anakinra in reducing the glycated haemoglobin in patients affected by rheumatoid arthritis and diabe...
    Medical condition: rheumatoid arthritis and type 2 diabetes mellitus as comorbidity.
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004859 10037740 RA LLT
    14.1 10027433 - Metabolism and nutrition disorders 10012601 Diabetes mellitus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2016-001857-42 Sponsor Protocol Number: EFC14822 Start Date*: 2018-05-09
    Sponsor Name:Hanmi Pharmaceutical Co., Ltd.
    Full Title: A 56-week, Multicenter, Double-blind, Placebo-controlled, Randomized Study to Evaluate the Efficacy and Safety of Efpeglenatide Once Weekly in Patients with Type 2 Diabetes Mellitus Inadequately Co...
    Medical condition: Type 2 diabetes mellitus
    Disease: Version SOC Term Classification Code Term Level
    21.1 10027433 - Metabolism and nutrition disorders 10067585 Type 2 diabetes mellitus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) DE (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2011-000400-17 Sponsor Protocol Number: JNJ28431754DIA3011 Start Date*: 2013-08-08
    Sponsor Name:Janssen-Cilag International NV
    Full Title: A Randomized, Double-Blind, 5-Arm, Parallel-Group, 26-Week, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Canagliflozin in Combination With Metformin as Initial Combinatio...
    Medical condition: Type 2 Diabetes Mellitus With Inadequate Glycemic Control With Diet and Exercise
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004861 10045242 Type II diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) CZ (Completed) SK (Completed)
    Trial results: View results
    EudraCT Number: 2017-003220-78 Sponsor Protocol Number: I8B-MC-ITSA Start Date*: Information not available in EudraCT
    Sponsor Name:Eli Lilly and Company
    Full Title: A Study to Evaluate the Pharmacokinetics and Glucodynamics of LY900014 Compared to Humalog in Children, Adolescents, and Adults with Type 1 Diabetes Mellitus
    Medical condition: Diabetes Mellitus, Type 1
    Disease: Version SOC Term Classification Code Term Level
    20.0 10027433 - Metabolism and nutrition disorders 10012601 Diabetes mellitus PT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2012-002635-28 Sponsor Protocol Number: OFT-Campos01-12 Start Date*: 2013-04-19
    Sponsor Name:AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI
    Full Title: ASSESSMENT OF THE EFFICACY OF SUBTENON NATURAL LEUCOCYTIC INTERFERON-α (IFNα) FOR THE TREATMENT OF DIABETIC MACULAR EDEMA (DME): A PILOT STUDY.
    Medical condition: DIABETIC MACULAR EDEMA (DME)
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004853 10057934 Diabetic macular edema LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-001895-72 Sponsor Protocol Number: Version1.0 Start Date*: Information not available in EudraCT
    Sponsor Name:Västerbottens läns landsting
    Full Title: VIP-VIZA intensive multimodal cardiovascular intervention sub-study - a phase 2 randomized controlled trial
    Medical condition: Cardiovascular disease - established artherosclerosis
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-002868-14 Sponsor Protocol Number: CLIK066B2201 Start Date*: 2017-04-18
    Sponsor Name:Novartis Pharma AG
    Full Title: A randomized, double-blind, dose-finding study to evaluate the change in weight after 24 weeks treatment with 8 doses of LIK066 compared to placebo in obese or overweight adults, followed by 24 wee...
    Medical condition: change in weight in obese or overweight adults
    Disease: Version SOC Term Classification Code Term Level
    20.0 10027433 - Metabolism and nutrition disorders 10029883 Obesity PT
    20.0 10027433 - Metabolism and nutrition disorders 10033307 Overweight PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed) CZ (Completed) AT (Completed) HU (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2017-002756-91 Sponsor Protocol Number: LPS14947 Start Date*: 2019-10-24
    Sponsor Name:Sanofi Aventis Groupe
    Full Title: A 12-week randomized, controlled trial to compare TOUJEO® and TRESIBA® in terms of glucose values in target range and variability during continuous glucose monitoring in patients with type 1 diabet...
    Medical condition: Type 1 Diabetes Mellitus
    Disease: Version SOC Term Classification Code Term Level
    21.1 10027433 - Metabolism and nutrition disorders 10067584 Type 1 diabetes mellitus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) GB (GB - no longer in EU/EEA) NL (Completed)
    Trial results: View results
    EudraCT Number: 2013-002244-86 Sponsor Protocol Number: REP0113 Start Date*: 2013-07-11
    Sponsor Name:Dompé s.p.a.
    Full Title: Effect of reparixin on long-term outcomes after pancreatic islet transplantation in type 1 diabetes mellitus patients. A non-interventional, monocentre study to extend up to 3 years the follow-up ...
    Medical condition: patients who have received pancreatic islet transplantation
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2020-000043-31 Sponsor Protocol Number: 383 Start Date*: 2020-03-26
    Sponsor Name:Groupe Hospitalier Paris Saint-Joseph
    Full Title: Efficacy and tolerance of Liraglutide for weight loss in obese type 2 diabetic hemodialysis patients
    Medical condition: obese type 2 diabetic hemodialysis patients
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-002752-50 Sponsor Protocol Number: IC2014-10 Start Date*: 2014-12-05
    Sponsor Name:INSTITUT CURIE
    Full Title: Phase II clinical trial evaluating the efficacy of the dual inhibition of PIK/Akt/mTor signaling pathway by PF-05212384 (PKI-587) for patients with myeloid neoplasm secondary to chemo-radiotherapy ...
    Medical condition: Myeloid neoplasm secondary to chemo-radiotherapy (t-AML/MDS) /or relapsed or refractory de novo AML /or de novo AML at diagnostic considered unfit to benefit from induction therapy with chemotherap...
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004864 10066572 AML progression LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-001289-14 Sponsor Protocol Number: MIT-Do001-C301 Start Date*: 2020-02-05
    Sponsor Name:Estetra SRL
    Full Title: A Randomized Double-blind Placebo Controlled Phase 3 Trial to evaluate the Efficacy and Safety of Estetrol for the Treatment of Moderate to Severe Vasomotor Symptoms in Postmenopausal Women (E4Comf...
    Medical condition: Moderate to Severe Vasomotor Symptoms (VMS) in Postmenopausal Women
    Disease: Version SOC Term Classification Code Term Level
    21.0 10047065 - Vascular disorders 10020407 Hot flashes LLT
    Population Age: Adults Gender: Female
    Trial protocol: PL (Completed) GB (GB - no longer in EU/EEA) SK (Completed) HU (Completed) LT (Completed) CZ (Completed) ES (Completed) IT (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2009-011221-13 Sponsor Protocol Number: SYR-322_104 Start Date*: 2011-09-30
    Sponsor Name:Takeda Global Research & Development Center, Inc.
    Full Title: A Comparative, Randomized, Open-Label, Multi-Center, Single Dose Pharmacokinetic, Pharmacodynamic and Safety Study of Alogliptin (12.5 mg and 25 mg) Between Children, Adolescents, and Adults with T...
    Medical condition: Type 2 diabetes mellitus
    Disease: Version SOC Term Classification Code Term Level
    14.1 10027433 - Metabolism and nutrition disorders 10045242 Type II diabetes mellitus LLT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2017-000387-14 Sponsor Protocol Number: RM-493-014 Start Date*: 2017-05-24
    Sponsor Name:Rhythm Pharmaceuticals, Inc.
    Full Title: Setmelanotide (RM-493) Phase 2 Treatment Trial in Patients with rare genetic disorders of obesity
    Medical condition: - POMC/PCSK1/LEPR heterozygous - POMC/PCSK1/LEPR compound heterozygous or homozygous deficiency obesity - POMC/PCSK1/LEPR composite heterozygous deficiency obesity - Smith-Magenis Syndrome - SH2B1...
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) ES (Ongoing) DE (Completed) FR (Ongoing) NL (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2019-004183-21 Sponsor Protocol Number: IP-001-18 Start Date*: 2022-08-19
    Sponsor Name:Iperboreal Pharma Srl
    Full Title: A Study to Evaluate the EffIcacy and Safety of XyloCore, a Glucose Sparing Experimental Solution, for Peritoneal Dialysis
    Medical condition: End-Stage Renal Disease (ESRD)
    Disease: Version SOC Term Classification Code Term Level
    21.0 10038359 - Renal and urinary disorders 10077512 End stage renal disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) IT (Trial now transitioned) DK (Trial now transitioned) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-000031-26 Sponsor Protocol Number: R256918DIA2001 Start Date*: 2007-12-18
    Sponsor Name:Janssen-Cilag International NV
    Full Title: A 12-Week, Double-Blind, Randomized, Placebo-Controlled Study in Type 2 Diabetes Mellitus Subjects to Evaluate the Efficacy, Safety and Tolerability of MTP Inhibitor JNJ-16269110
    Medical condition: Diabetes
    Disease: Version SOC Term Classification Code Term Level
    9.1 10018424 Glucose metabolism disorders (incl diabetes mellitus) HLGT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) FI (Completed) NL (Completed) SE (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2020-000763-23 Sponsor Protocol Number: ANJ900D3501 Start Date*: 2021-12-28
    Sponsor Name:Anji Pharma (US) LLC
    Full Title: A Randomized, Multicenter, Double-Blind, Parallel-Group, Placebo- and Comparator-Controlled Study to Compare the Glycemic Effects, Safety, and Tolerability of Metformin Hydrochloride Delayed-Releas...
    Medical condition: Type 2 Diabetes Mellitus with varying renal function from normal up to CKD3B
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004861 10045242 Type II diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) PL (Completed) BG (Completed) HU (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 30 10:38:10 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA